Company news: two drugs clear FDA panel
Gilead Sciences landed a 13-1 FDA panel vote for its HIV quad pill. The daily Truvada/elvitegravir integrase/cobicistat compound was tested for HIV patients who are on their first round of medical therapy. One nephrologist voted against the drug – kidney safety was a concern among panelists. Jefferies analyst Thomas Wei said in a research note that one panelist said the drug's once-a-day regimen and lack of CNS side effects made the combo appealing. It is expected to go up for a full FDA vote by August 27.